High-risk neuroblastoma (NBL) Program in Pharmaceutical Benefits Scheme (PBS) 012-25070740

This document outlines details of PBS-subsidised eflornithine for patients with high-risk neuroblastoma (NBL).

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

Restrictions	Authority level and section	PA assessment	Processing system	Prescriber type	Prescriber self-serve
Initial PB384 form	Written Electronic S85: eflornithine	No	OPA	Must be treated in a hospital/cancer centre by a: paediatric oncologist haematologist	Yes - delayed assessment due to high cost
Grandfather	Telephone Electronic S85: eflornithine	No	OPA	Must be treated: in a hospital/cancer centre by a paediatric oncologist or a haematologist by a medical practitioner under the direct supervision of a paediatric oncologist or a haematologist	Yes
Continuing	Telephone Electronic S85: eflornithine	No	OPA	Must be treated: in a hospital/cancer centre by a paediatric oncologist or a haematologist by a medical practitioner under the direct supervision of a paediatric oncologist or a haematologist	Yes

Operational Information